Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-3921

This is a description of a medication called OXcarbazepine. It is in tablet form and each tablet contains 300 mg of the active ingredient. The medication is manufactured by Camber Pharma, Inc in Piscataway, NJ. The NDC (National Drug Code) number for this medication is 70518-3921-01. The lot number and expiration date are not readable. The medication should be stored at a temperature between 20-25°C (58-77°F), with excursions permitted to 15.30°C (59-86°F). It is important to keep this medication out of the reach of children. The medication has been repackaged by RemedyRepack Inc., located in Indiana, PA.*

OXcarbazepine is a medication available in the form of tablets, with each tablet containing 300 mg of the active ingredient. The tablets are sold in a box with 100 tablets. The medication is only available with a prescription. The product is labeled with an NDC number: 70518-3921-00. The lot number and expiration date are not provided in the given text. The source NDC number is 31722-0024-01, indicating the manufacturer of the medication as Camber Pharma, Inc in Piscataway, NJ 08854. The text also mentions storing the medication at a temperature range of 20-25°C (58-77°F) and allowing excursions to 15.30°C (59-86°F) as per USP guidelines. The medication should be kept out of the reach of children. The repackaging of the medication is done by RemedyRepack Inc. in Indiana, PA 15701. They can be contacted at 724.465.8762. Overall, this text provides useful information about the medication, its strength, packaging, manufacturer, and storage instructions.*

The text provided contains the results of a log-rank test. The p-value obtained from the test is 0.0001, suggesting a statistically significant difference. The text also includes a table or graph showing the time on trial from Day 2 to Day 11 for a treatment group called "Oxcarbarspine." Unfortunately, the table or graph itself is not available in the provided text.*

There is a log-rank test result with a p-value of 0.0001. The text also includes a list of numbers related to time to exit (days) in a treatment group, with the group labeled as "HIGH - LOW."*

The text appears to be an output from a statistical analysis. The log-rank test was conducted, resulting in a p-value of 0.0001. The subsequent section seems to include data points for "S RARANLARls REARRuANS" and a time to exit measurement. The treatment groups are identified as "HIGH - LOW".*